GlassScriptPhysician profile
Samantha Dewitt
NPI 1134674807
$3,261.12
in general payments reported to CMS, 2019-2025
31 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.63 · 2023: $838 · 2024: $1,167 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $537.32 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $435.84 | 2023-2025 | Lifevest |
| Amgen INC. | $255.14 | 2023-2025 | Repatha, Repatha, Evenity |
| Lilly USA, LLC | $232.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $228.94 | 2021-2025 | |
| Boston Scientific Corporation | $211.48 | 2023-2025 | Bodyguardian, Watchman Access System, Cds - Mct/Cem Monitoring |
| Merck Sharp & Dohme LLC | $211.33 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Novo Nordisk INC | $183.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $157.42 | 2025 | Amvuttra, Onpattro |
| Corcept Therapeutics | $134.40 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $79.57 | 2023-2024 | Gvoke Hypopen |
| Baxter Healthcare | $75.09 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $75.07 | 2023-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $62.64 | 2024-2025 | |
| Halozyme INC | $49.53 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $40.70 | 2024 | |
| Abbvie INC. | $35.59 | 2021 | |
| Edwards Lifesciences Corporation | $28.49 | 2025 | Sapien 3 Ultra Resilia |
| Siemens Medical Solutions USA, INC. | $22.54 | 2023 | Acuson Sequoia Diagnostic Ultrasound System |
| Kestra Medical Technology Services, INC. | $21.77 | 2025 | Assure Wcd |
| United Therapeutics Corporation | $20.12 | 2025 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $19.49 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.01 | 2023 | Opsumit, Uptravi |
| Aimmune Therapeutics, INC. | $16.72 | 2025 | Vowst |
| Inspire Medical Systems, INC. | $16.52 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $16.06 | 2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $15.83 | 2024 | Farxiga |
| Atricure, INC. | $14.98 | 2024 | |
| Insulet Corporation | $14.82 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2025 | Eliquis |
| Mannkind Corporation | $14.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.